Beijing Luzhu Biotechnology Co., Ltd. (02480.HK) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 5Aug 10Aug 13Aug 18Aug 21Aug 26Aug 31Sep 3

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

—

Market Cap

HKD 2.69B

MomentumView details →

1D Return

+0.00%

YTD Return

−42.80%

RSI (14)

52.7

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

—

Market Cap

HKD 2.69B

RSI (14)

52.7

MomentumView details →

1D Return

+0.00%

YTD Return

−42.80%

ProfitabilityView details →

Gross Margin

—

Net Margin

—

EBITDA Margin

—

ROE (TTM)

—

ROA (TTM)

—

Asset Turnover

—

GrowthView details →

Revenue YoY

—

EPS YoY

—

FCF YoY

—

Revenue CAGR 3Y

—

EPS CAGR 3Y

—

EBITDA YoY

—

EarningsView details →

EPS (Actual)

−HKD 0.05

EPS Surprise

—

Beats (12Q)

—

Next Q EPS Est

—

Avg Surprise (4Q)

—

Rev Surprise

—

Capital & dividendView details →

Debt/Equity

—

Current Ratio

—

Quick Ratio

—

Div Yield

—

Div Rate

—

Div Growth 1Y

—

Financials snapshotView financials →

Revenue (TTM)

—

Net Income (TTM)

—

Op. CF (TTM)

—

Next earningsMar 24, 2027 →

Latest newsMore news →

Green Bamboo Biotech announced that the Phase III clinical trial results of its core product LZ901 vaccine in China were published in Nature Communications on August 7, 2026, showing high protective efficacy and good safety in preventing herpes zoster in adults aged 40 and above.26d ago

Similar companies

Nurix Therapeutics, Inc.NRIX Clover Biopharmaceuticals, Ltd.02197.HK Frontage Holdings Corporation01521.HK BioDlink International Company Limited01875.HK Soleno Therapeutics, Inc.SLNO Viridian Therapeutics, Inc.VRDN Find similar companies →

Latest newsMore news →

Green Bamboo Biotech announced that the Phase III clinical trial results of its core product LZ901 vaccine in China were published in Nature Communications on August 7, 2026, showing high protective efficacy and good safety in preventing herpes zoster in adults aged 40 and above.26d ago